Lumida
/TLSI
⌘K
TriSalus Life Sciences Inc

TriSalus Life Sciences Inc

TLSI
$4.67USD-0.74%-0.04 today

MARKET CAP

287.2M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$2
$8

AI Summary

Stalk
StalkMedium

TLSI is in an early/fragile Stage 1 base after the mid-May flush; long-term downtrend remains intact but short-term EMAs have repaired and the Bullish Pivot Point signals structural repair. Price is oscillating in a tightening range above support but is extended above rising EMAs, so the medium-term bias is bullish while execution is best deferred. The strategy is to stalk pullbacks into the rising 9/21 EMA support zone in anticipation of a breakout.

  • Q1 2026 revenue $8.9M drives revised FY26 guidance of $54–$57M
  • 52% YoY revenue growth underscores strong PEDD system adoption
  • FDA delays postpone Trinav Advance launch, reducing H2 revenue visibility
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$18.5M$29.4M$45.2M
YoY %+59.0%+53.4%
P / Sales4.2x4.3x5.9x
EV / Sales6.3x5.7x6.9x
Gross Profit, Adj.$15.9M$25.3M$38.2M
YoY %+59.2%+50.8%
Margin %85.9%86.1%84.6%
EV / Gross Profit7.4x6.6x8.2x
EBITDA, Adj.$-53.7M$-35.4M$-26.3M
YoY %+34.1%+25.7%
Margin %-290.4%-120.4%-58.3%
EV / EBITDA-2.2x-4.8x-11.9x
EBIT$-54.5M$-36.2M$-26.9M
YoY %+33.6%+25.5%
Margin %-294.3%-122.9%-59.7%
EV / EBIT-2.2x-4.7x-11.6x
Net Income$-63.6M$-33.2M$-69.7M
YoY %+47.7%-109.7%
Net Margin-343.6%-112.9%-154.3%
EPS (GAAP)-$6.77-$1.31-$1.84
YoY %+80.6%-40.5%